NewsBenzingaJP Morgan inicia cobertura sobre Enliven Therapeutics con calificación de sobreponderar y anuncia un precio objetivo de 75 dólares JP Morgan inicia cobertura sobre Enliven Therapeutics con calificación de sobreponderar y anuncia un precio objetivo de 75 dólares Benzinga 2026.10.01 14:46 (GMT+0) Open on Benzinga Other news Versant Signs Multi-Year Renewal Distribution Deal With Verizon For Its Portfolio Of Products Evercore ISI Group Maintains In-Line on Nike, Lowers Price Target to $28 CJ CheilJedang, ADM Agree To Create Joint Venture Over Source Of Feed-Grade Amino Acids For U.S. Livestock Sector Evercore ISI Group Maintains In-Line on EastGroup Properties, Lowers Price Target to $199 RBC Capital Initiates Coverage On Uranium Energy with Sector Perform Rating, Announces Price Target of $10 AST SpaceMobile Stock Trades Flat Following B.Riley Price Target Cut to $65
CJ CheilJedang, ADM Agree To Create Joint Venture Over Source Of Feed-Grade Amino Acids For U.S. Livestock Sector
RBC Capital Initiates Coverage On Uranium Energy with Sector Perform Rating, Announces Price Target of $10
